ClearNote Health

ClearNote Health is developing liquid biopsy tests for the early detection of cancers with high mortality rates. Early detection of cancer offers clinicians and their patients a better way to identify cancers at a more treatable stage. To achieve this, ClearNote is using their proprietary epigenomic platform that combines biology and AI to identify DNA-based changes in biology as cancer develops from a standard blood draw. In particular, ClearNote detects the epigenomic mark 5-hydroxymethylcytosine (5hmC) that has previously been identified as a cancer biomarker. ClearNotes’s technology tags and enriches DNA fragments that contain 5hmC so that they can be sequenced. The 5hmC mark is sensitive, stable and precise enough to detect both the presence of cancer and the type.